An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam Plus Vancomycin, Linezolid Versus Standard Of Care Plus Vancomycin, Linezolid As Empiric Therapy In Febrile Neutropenic Adults With Cancer

Trial Profile

An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam Plus Vancomycin, Linezolid Versus Standard Of Care Plus Vancomycin, Linezolid As Empiric Therapy In Febrile Neutropenic Adults With Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2018

At a glance

  • Drugs Ceftazidime/tazobactam (Primary) ; Cefepime; Linezolid; Meropenem; Piperacillin/tazobactam; Vancomycin
  • Indications Bacterial infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 May 2018 Status changed from not yet recruiting to recruiting.
    • 11 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jun 2018.
    • 05 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top